Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Although GLP-1 medications have transformed obesity treatment, there remains a significant need for rigorous data examining how these therapies affect fertility and reproductive function in this population. The RESTORE study is currently evaluating semaglutide treatment in girls and women with PMOS and obesity, with the overarching goal of determining whether weight loss and metabolic improvements can restore ovulation and improve reproductive outcomes
not a therapeutic equivalent or generic of any FDA-approved tirzepatide
The study was supported by Slovenian Research Agency grants #P3-0298, #P3-0343
Since retatrutide does not hold MHRA or EMA marketing authorisation, no SmPC, PIL, or NICE guidance specific to this compound is available to the public
More details on this evolving situation are available in our coverage of peptide regulation news
The results in the STEP TEENS trial were very similar to the (adult) STEP results
US$ 28.01
:format(webp))
US$ 27.84
US$ 24.97
